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The first generation of e-cigarettes appeared 
on the EU market in 2006 and soon after it was 
introduced in the United States. It seems to be 
very difficult to compare health effects of all of 
the three generations. Differences are related to 
the satisfaction of using the variety of flavouring 
agents and more acceptable devices. 
E-cigarettes are manufactured mainly in 
China. There are high or even extremely high 
differences in product engineering, nicotine 
concentrations, and quality of other compounds 
used as carriers neccessary to produce vaporizing 
aerosols.
A frequently described dangerous issue is the 
possibility of modifying devices for using them 
to deliever  marijuana or other drugs. Till now 
almost 2500 papers have presented variable data 
about individual health effects and the impact of 
e-smoking on public health. 
It is commonly accepted that e-cigarettes are 
less harmful than tobacco smoking especially to 
the lungs and cardiovascular system. However, 
especially for cancerogenic agents, even small 
risks of adverse effects should be regarded as 
unacceptable. One should remember that for 
such agents there are no low limits of doses or 
concentrations in inhaled air. In fact concentra-
tions of formaldehyde, an undoubtful cancero-
genic agent, classified by IARC (International 
Agency for Research on Cancer)  as the 1 group, 
in e-cigarettes vary between many products, in 
some of them exceeding concentration in tobacco 
cigarettes. Acrolein is also present in e-cigarettes 
in concentrations responssible for irritant and 
inflammmatory effects of airways. Exposure to 
propylene glycol and glycerin as ingredients of 
the liquid causes not only eye and airway irrita-
tion, but also affects the central nervous system, 
behaviour and the spleen.
For pneumologists and from toxicological 
point of view, it seems to be very important that 
the size of the particles distributed in aerosol 
from e-cigarettes is in the respirable range that 
leads to alveolar deposition. The liquid produces 
lung inflammation, pulmonary oxidative stress, 
diminishes levels of glutathione, thus changing 
the oxidation/antioxidation balance. 
An unexpected result of the use of e-ciga-
rettes is explosion and fire that was recently 
described [1].
A number of e-smokers has rapidly incre-
ased over recent years. In 2010, a total of 1.8% 
of adult Americans used e-cigarettes but the rate 
rosed to 13% by 2013 [2]. Poland is a country of 
one of the highest number of e-cigarettes young 
users since 19% of people below 20, who never 
smoked tobacco and 57% of current smokers use 
e-cigarettes [3]. Although tobacco smokers are 
most likely to be current users of e-cigarettes, 
one third of current e-cigarettes users have never 
been tobacco smokers. A survey of American col-
lege students revealed that e-cigarette use is not 
motivated by the desire to stop tobacco smoking. 
Almost 300,000 school students reported having 
used e-cigarettes, they were mostly convinced no 
dangers of e-cigarette were proved. 
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Many doctors and the expert consensus 
recommmend the use e-cigarettes as a smoking 
cessation aid. However, surveys and observatio-
nal studies have yielded conflicting results. Five 
studies found no association between e-smoking 
and quitting convencional cigarettes, and only 
one found documented reduction of the number 
of cigarettes smoked per day. An interesting Ita-
lian study on a comparison of the effectiveness of 
nicotine content of e-cigarettes and cigarettes that 
did not deliever nicotine showed no differences in 
reduction of the number of conventional cigaret-
tes smoked per day during 1 year of the observa-
tion [4]. One study reported that switching from 
conventional to e-cigarettes in asthmatic patients 
may improve symptoms and lung function [5].
In this issue of „Advances in Respiratory 
Medicine” we can find interesting discussion pro/
contra in the context of neccessary statement of 
Polish experts  [6,7]. One paper showed many 
influences of e-cigarettes on cells, lung function, 
lung development and diseases progress that 
should be considered. Moreover, some studies 
indicate that the use of e-cigarettes significantly 
increases the risk of a following tobacco smoking 
among young people. It might be explained by 
the fact of rapid absorption of nicotine from the 
lung in contrast to the agents absorbed from the 
gastrointestinal tract when gums are used for 
quitting tobacco smoking habit.  In another pre-
sented study [8], one can find an observation that 
the intensity of e-smoking is larger than tobacco 
smoking among students of medicine in one of 
the largest medical school in Poland. It suggests 
a potential increase of tobacco smoking in the 
next years. In contrast, the author presented 
results a study on motivation, where an attempt 
to quit tobacco smoking was the most frequently 
reported factor. However, no convincing data on 
effectiveness of switching from tobacco to e-ci-
garettes exist. Many authors indicate a liability 
to nicotine-rich e-cigarettes and a future switch 
to conventional smoking habit. 
NIH workshop in 2015 presented almost 50 
research gaps that should be explained before the 
recommendation might be accepted [9]. It seems 
however, that doctors can use this method in the 
practice only as an aid of smoking cessation in 
some individuals. Special caution of switching 
should be recommended in pregnant women. 
Although some countries accepted e-cigarettes 
in pregnant smokers, others did not. There is 
also a need for establishing standard contents of 
nicotine and other potential harmful agents and a 
permanent monitoring of a quality of e-cigarettes 
on different markets. 
We can conclude that it is too early to recom-
mend the common use of e-cigarettes in a struggle 
against nicotine addiction, especially in young 
people. Health effects, in particular cancerogenic 
ones, have yet to be explored. Health systems 
should start controlling markets with respect to 
the quality of delivery systems and contents of 
nicotine and vaporized additives in available e-ci-
garettes. Many aspects still wait for explanation.
Conflict of interest
The author declares no conflict of interest.
References:
1. Brownson EG, Thompson CM, Goldsberry S, et al. Explosion In-
juries from E-Cigarettes. N Engl J Med. 2016; 375(14): 1400–1402, 
doi: 10.1056/NEJMc1608478, indexed in Pubmed: 27705271.
2. McMillen RC, Gottlieb MA, Shaefer RM, et al. Trends in Elec-
tronic Cigarette Use Among U.S. Adults: Use is Increasing 
in Both Smokers and Nonsmokers. Nicotine Tob Res. 2015; 
17(10): 1195–1202, doi: 10.1093/ntr/ntu213, indexed in Pub-
med: 25381306.
3. Electronic Nicotine Delivery Systems. Pediatrics. 2015; 136(5): 
1018–1026, doi: 10.1542/peds.2015-3222.
4. Caponnetto P, Campagna D, Cibella F, et al. EffiCiency and 
Safety of an eLectronic cigAreTte (ECLAT) as tobacco ciga-
rettes substitute: a prospective 12-month randomized control 
design study. PLoS ONE. 2013; 8(6): e66317, doi: 10.1371/
journal.pone.0066317, indexed in Pubmed: 23826093.
5. Polosa R, Morjaria JB, Caponnetto P, et al. Persisting long term 
benefits of smoking abstinence and reduction in asthmatic 
smokers who have switched to electronic cigarettes. Discov 
Med. 2016; 21(114): 99–108, doi: 10.1016/j.jaci.2015.12.017, 
indexed in Pubmed: 27011045.
6. Zielonka TM. A debate: Can we recommend electronic ciga-
rettes to our patients? Opinion 1. Adv Respir Med. 2017; 86: 
35–39. doi: 10.5603/ARM.2017.0007.
7. Poznański M. A debate: Can we recommend electronic ciga-
rettes to our patients? Opinion 2. Adv Respir Med. 2017; 86: 
40–45. 10.5603/ARM.2017.0008. 
8. Brożek G, Jankowski M, Zejda J, Jarosińska A, Idzik A, Bań-
ka P. E-smoking among students of medicine — frequency, 
pattern and motivations. Adv Respir Med. 2016; 85: 8–14. 
doi:  10.5603/ARM.2017.0003.
9. Walton KM, Abrams DB, Bailey WC, et al. NIH electronic ci-
garette workshop: developing a research agenda. Nicotine Tob 
Res. 2015; 17(2): 259–269, doi: 10.1093/ntr/ntu214, indexed in 
Pubmed: 25335949.
